National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
157
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Clostridium tetani Tetanus toxoid is now administered routinely to most children in the United States. Hence, cases of tetanus in the United States may occur in the elderly, who may not have been immunized. The elderly seem to have a blunted response to booster doses of tetanus toxoid; this problem with efficacy in a portion of the population probably does not call for development of a new vaccine.

Chlamydia

The Chlamydia trachomatis species contains various strains that are the etiologic agents of lymphogranuloma venereum (LGV), trachoma, and various other syndromes. There are at least 15 serotypes of C. trachomatis: three are associated with LGV and 12 are considered trachoma strains, although the symptoms they produce range from acute and chronic eye disease, urethritis in males, and genital tract infection in females, to acute ocular and respiratory tract infections in newborns and young infants (Grayston and Wang, 1978). C. trachomatis is now considered a major cause of sexually transmitted disease (e.g., mucopurulent cervicitis).

C. trachomatis is not a suitable candidate for vaccine control at this time for both biological and public health reasons (NIAID, 1984). There is little evidence of natural immunity. Results from trials with an inactivated vaccine suggest that chronic eye disease with pannus formation may result from heterotypic infection: eye disease was accentuated in vaccine recipients who later became infected with another serotype (Craighead, 1975). Field studies in Taiwan and India with multiple doses of an inactivated vaccine failed to show long-term protection (Grayston and Wang, 1978).

The number of genital and neonatal infections caused by C. trachomatis strains probably could be reduced substantially by standard public health measures, including contact tracing. Efforts also are underway to modify some antibiotic treatment protocols, i.e., for gonorrhea to ensure killing of chlamydiae which are often isolated either alone or with gonococci from cultures of patients with urethritis (Bowie and Holmes, 1979).

Entamoeba histolytica

The E. histolytica ameba frequently is found living as a commensal in the lumen of the human large intestine, producing large numbers of infective cysts that are transmitted by the fecal-oral route. It also may produce invasive amebiasis, however, with symptoms ranging from mild dysentery to life-threatening fulminant, hemorrhagic infection with high fever. Liver invasion with abscess formation also may occur.

While amebiasis is not common in the U.S., loci exist in both institutional and non-institutional settings (Krogstad et al., 1978). Prevalence rates among male homosexuals may range from 20 to 30 percent in some large cities (Kean, 1976, 1981; Phillips et al., 1981; Pomerantz et al., 1980).

Page
157
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)